Chitosan
In clinical developmentRecent clinical, regulatory, research and industry developments relating to this drug.
Magnetically recoverable Fe3O4-chitosan/PVA hydrogel for photo-Fenton degradation of diazinon
Novel nano-reinforced chitosan derivatives for adsorption of heavy metal ions from aqueous media
Preparation and identification of chitosan and chitosan nanoparticles from crab byproducts
Effect of Shockwaves on Fallopian Tubes Adhesion: a Randomized Controlled Trial
A review of current advancements for wound healing: Biomaterial applications and medical devices.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- International journal of molecular sciences3
- Nature communications2
- Journal of biomedical materials research. Part B, Applied biomaterials1
- Journal of the American Chemical Society1
- Molecules (Basel, Switzerland)1
- Li Q2
- Liu J2
- Liu Y2
- Aachmann FL1
- Ali MA1
- Chen L1
- Chen Q1
- Deng X1
- Advanced Environmental Research Laboratories1
- Centre for Bioengineering & Nanomedicine (Dunedin)1
- Comenius University in Bratislava1
- Engineering Research Center of Agricultural Microbiology Technology1
- Frontier Institute of Science and Technology and State Key Laboratory for Mechanical Behavior of Materials1
- Institute of Functional Nano & Soft Materials (FUNSOM)1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 2 of the same disease areas as Chitosan in the shared literature.
Studied across 2 of the same disease areas as Chitosan in the shared literature.
Studied across the same disease area as Chitosan in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials